Suzhou Ruihui Biomedical R D Center

Suzhou Ruihui Biomedical is a clinical-stage biopharmaceutical company based in the Suzhou Industrial Park, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH), as well as select oncology targets. Its lead candidate, RH001, is an orally available small molecule GLP-1 receptor agonist designed to offer a more convenient alternative to traditional injectable treatments. Ruihui's R&D strategy leverages a deep understanding of medicinal chemistry to optimize high-potency compounds for chronic disease management. The company is led by industry veterans with significant experience in global pharmaceutical research and development.